source
- TCGX uses SPAC to take migraine biotech TriGemX public, securing $246M for phase-3 trialTCGX, a life‑sciences investment firm, announced it will merge its SPAC with TriGemX Bio, a biotech focused on migraine treatments. TriGemX, formerly known as Kallyope, is developing a TRPM8 chann…
- Gilead reports positive Phase 2 results for oral ulcerative colitis drugGilead announced that its experimental oral therapy for ulcerative colitis achieved positive results in a Phase 2 trial. The study reported that patients receiving the drug showed measurable clini…